Point Reached in Targeted Therapy; Where are we?

Havva Yeşil Çınkır

doi:10.5152/EurJTher.2018.1005

Authors

Havva Yeşil Çınkır Department of Medical Oncology, Gaziantep University School of Medicine, Gaziantep, Turkey

DOI:

https://doi.org/10.5152/EurJTher.2018.1005

Keywords:

Epidermal growth factor receptor (EGFR), Anaplastic lymphoma kinase (ALK), immunotherapy, lung cancer

Abstract

Lung cancer is a very important public health problem. Identification of new molecular targets and development of novel therapies related to activated immune cytotoxic cells are significant steps in achieving the goal of personalized therapy in lung cancer.

Metrics

Metrics Loading ...

References

Yüce D, Kılıçkap S. Epidemiology and Etiology. Turkiye Klinikleri Radiat Oncol-Special Topics 2018; 4: 1-7.

Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013; 31: 1039-49.

Griffin R, Robert RA. Molecular Targets in Non-Small Cell Lung Cancer. Ochsner J 2017; 17:388-92.

Levy MA, Lovly CM, Pao W. Translating genomic information into clinical medicine: Lung cancer as a paradigm. Genome Res 2012; 22: 2101-8.

Weinstein IB. Cancer. Addiction to oncogenes - The Achilles heal of cancer. Science 2002; 297: 63-4.

Demir M, Kılıçkap S. Targeted Therapy and Biological Agents. Turkiye Klinikleri Radiat Oncol-Special Topics 2018; 4: 86-92.

Puri T. Targeted therapy in nonsmall cell lung cancer. Indian J Cancer 2017; 54: 83-8.

Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014; 9: 154-62.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.

Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013; 8: 823-59.

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-46.

Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive nonsmall-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 2015; 26: 1883-9.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.

Maemondo M, Inoue A, Kobayashi K, Sugara S, Ouzimu S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-8.

Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-34.

Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced nonsmall-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 213-22.

Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16: 141-51.

Park K, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label,randomised controlled trial. Lancet Oncol 2016; 17: 577-89.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattanna T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378: 113-25.

Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, et al. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res 2013; 19: 2584-91.

Sequist LV, Waltman BA, Dias-Santagata D,Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.

Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 2017; 376: 629-40.

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4 ALK fusion gene in non small celllung cancer. Nature 2007; 448: 561-6.

Shames DS, Wistuba II. The evolving genomic classification of lung cancer. J Pathol 2014; 232: 121-33.

Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK positive lung cancer. N Engl J Med 2013; 368: 2385-94.

Solomon BJ, Mok T, Kim DW, Wu Y-L, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 2167-77.

Crino L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, et al. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. J Clin Oncol 2016; 34: 2866-73.

Felip E, Orlov S, Park K, Yu CJ,Tsai MC, Nishio M, et al. ASCEND-3: A Single-Arm, Open-Label, ulticenter Phase II Study of Ceritinib in ALKINaïve Adult Patients (pts) with ALKRearranged (ALK+) NonSmall Cell Lung Cancer (NSCLC). J Clin Oncol 2015.

Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, et al. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol 2016; 34: 661-8.

Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017; 390: 29-39.

Doebele RC. A nice problem to have: when ALK inhibitor therapy works better than expected. J Thorac Oncol 2014; 9: 433-5.

Ou SHI, Bang YJ, Camidge DR, Riely GJ, Salgia R, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced ROS1 rearranged non small cell lung cancer (NSCLC). J Clin Oncol 2013; 31.

Minuti G, D’Incecco A, Cappuzzo F. Targeted therapy for NSCLC with driver mutations. Expert Opin Biol Ther 2013; 13: 1401-12.

Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: 17.

Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, et al. Selumetinib plus docetaxel for KRAS mutant advanced non small cell lung cancer: A randomised, multicentre, placebo controlled, phase 2 study. Lancet Oncol 2013; 14: 38-47

Mason I. Initiation to end point: The multiple roles of fibroblast growth factors in neural development. Nat Rev Neurosci 2007; 8: 583-96.

Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non small cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26: 2450-6.

Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first line therapy for nonsquamous non small cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-34.

Antonia SJ, Villegas A, Daniel D,Vicente D, Murakami S, Hui R, et al; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377: 1919-29.

Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, et al.Pembrolizumab versus Chemotherapy for PD-L1 Positive NonSmall-Cell Lung Cancer. N Engl J Med 2016; 375: 1823-33.

Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016; 17: 1497-508.

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. CFirst-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 2017; 376: 2415-26.

Brahmer J, Reckamp KL, Baas P,Crino L, Eberhardt WEE, Poddusskaya E, et al.Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373: 123-35.

Kılıçalp S. Immunotherapy. Turkiye Klinikleri J Radiat Oncol-Special Topics 2018; 4: 93-6.